Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia

Eunice S. WangRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA; Correspondence[email protected]

Richard AplencThe Children’s Hospital of Philadelphia, Philadelphia, PA, USA;

Deborah ChirnomasPfizer Inc, New York, NY, USA;

Michael DuganFranciscan Alliance, Indianapolis, IN, USA;

Salman FazalAllegheny Health Network, Pittsburgh, PA, USA;

Swaminathan IyerHouston Medical Center, Houston, TX, USA;

Tara L. LinUniversity of Kansas Medical Center, Kansas City, KS, USA;

Sucha NandLoyola University Medical Center, Maywood, IL, USA;

Kristen J. PiercePfizer Inc, Groton, CT, USA;

Paul J. ShamiHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA;

Jennifer J. VermettePfizer Inc, Cambridge, MA, USA;

Camille N. AbboudWashington University Medical School, St. Louis, MO, USA

Your download is now in progress and you may close this window